Evidence map›Paper›PMID 30410998›Full record

ArticleJournal of tropical diseases & public health2018

Sickle Cell Disease Clinical Trials and Phenotypes.

Chinedu A Ezekekwu, Taiwo R Kotila, Titilola S Akingbola, Guillaume Lettre, Victor R Gordeuk, Richard S Cooper, Michael R DeBaun, Baba Inusa, Bamidele O Tayo, Africa Sickle Cell Research Network

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of tropical diseases & public health, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Chinedu A EzekekwuDepartment of Hematology, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Taiwo R KotilaDepartment of Hematology, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Titilola S AkingbolaDepartment of Hematology, College of Medicine, University of Ibadan, Ibadan, Nigeria.
Guillaume LettreMontreal Heart Institute, Montréal, QC H1T 1C8, Canada.
Victor R GordeukDivision of Hematology & Oncology, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA.
Richard S CooperDepartment of Public Health Sciences, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA.
Michael R DeBaunGuy's and St. Thomas Foundation Trust, London, United Kingdom.
Baba InusaDivision of Hematology/Oncology, Department of Pediatrics, Vanderbilt Meharry, Center of Excellence in Sickle Cell Disease, Children's Hospital at Vanderbilt, Nashville, USA.
Bamidele O TayoDepartment of Public Health Sciences, Loyola University Chicago Stritch School of Medicine, Maywood, IL, USA.
Africa Sickle Cell Research Network

Funding

Doris Duke Charitable Foundation 2013140
6 · The paper itself

Abstract

Sickle cell disease, one of the world's most common genetic disorders is prevalent in sub-Saharan Africa. The trans-Atlantic slave trade accounted for the gene movement from Africa to the Caribbean and United States of America and lately, migration has resulted in the introduction of the gene to the United Kingdom and other parts of Europe. Different haplotypes exist, however the differences in these haplotypes are not sufficient to explain the different clinical variations within the same region or different settings.

Indexed as

Clinical phenotypesHaplotypesMalariaSickle cell disease

Identifiers

PMID30410998
PMCPMC6219473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.